✦ LIBER ✦

844 A phase II study testing intravenous (iv) vinflunine (VFL) as second line therapy in patients with advanced transitional cell cancer (TCC) of the bladder

✍ Scribed by S. Culine; C. Théodore; M. De Santis; B. Bui; T. Demkow; J. Lorenz; F. Rolland; F. Fabry; B. Longerey; N. James

Book ID: 118621011
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 168 KB
Volume: 1
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(03)90870-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Methotrexate-paclitaxel-epirubicin-carbo

Methotrexate-paclitaxel-epirubicin-carboplatin as second-line chemotherapy in patients with metastatic transitional cell carcinoma of the bladder pretreated with cisplatin-gemcitabine: A phase II study

✍ Amal Halim; Niveen Abotouk 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 139 KB

PD-070 SIGN: A Phase II, open-label, ran

PD-070 SIGN: A Phase II, open-label, randomized study comparinggefitinib (IRESSA) with docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer

✍ Cufer, T.; Vrdoljak, E. 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 138 KB

6568 POSTER Phase II trial of the novel

6568 POSTER Phase II trial of the novel epothilone ZK-EPO as second-line therapy in patients with stage IIIB or stage IV non-small-cell lung cancer

✍ Gatzemeier, U.; vonPawel, J.; Eschbach, C.; Brune, A.; Wagner, A.; Giurescu, M.; 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 61 KB

Phase II study of pemetrexed disodium, a

Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma : A study of the national cancer institute of Canada clinical trials group

✍ Frances A. Shepherd; Janet Dancey; Andrew Arnold; Alan Neville; James Rusthoven; 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 3 views

## Background: Pemetrexed disodium (alimta [eli lilly and company, indianapolis, in], ly231514, multitargeted antifolate) is a new multitargeted antifolate agent that inhibits multiple enzymes in the folate pathway. phase ii trials showed single-agent response rates of 16% and 23% in untreated pati

Prospective, multicenter, randomized, in

Prospective, multicenter, randomized, independent-group, open-label phase II study to investigate the efficacy and safety of three regimens with two doses of sagopilone as second-line therapy in patients with stage IIIB or IV non-small-cell lung cancer

✍ Heigener, David F.; von Pawel, Joachim; Eschbach, Corinna; Brune, Andreas; Schmi 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 316 KB